European Commission Approves Acadia’s DAYBU For Rett Syndrome Patients Aged Five And Older Following Successful Phase 3 LAVENDER Study
Share
Why It Matters
Acadia got permission from Europe to sell a new medicine called DAYBU for kids with Rett Syndrome who are five or older, after tests showed it works. This is good news because it means the company can now help more patients and potentially make money from this medicine in Europe.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.